About Scynexis
Scynexis is a company based in Jersey City (United States) founded in 1999.. Scynexis has raised $62.65 million across 9 funding rounds from investors including Société Générale, SLR Investment Corp and Burrill and Company. The company has 28 employees as of December 31, 2024. Scynexis offers products and services including SCY-247 and Ibrexafungerp. Scynexis operates in a competitive market with competitors including F2g, Amplyx Pharmaceuticals, Biosergen, Elion Therapeutics and Viamet Pharmaceuticals, among others.
- Headquarter Jersey City, United States
- Employees 28 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Scynexis, Inc.
-
Annual Revenue
$3.75 M-97.33as on Dec 31, 2024
-
Net Profit
$-21.29 M-131.75as on Dec 31, 2024
-
EBITDA
$-37.12 M-150.51as on Dec 31, 2024
-
Total Equity Funding
$62.65 M (USD)
in 9 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Apr 09, 2020
-
Investors
Société Générale
& 10 more
-
Employee Count
28
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Scynexis
Scynexis is a publicly listed company on the NASDAQ with ticker symbol SCYX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Scynexis
Scynexis offers a comprehensive portfolio of products and services, including SCY-247 and Ibrexafungerp. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Second-generation agent for treating invasive fungal infections
Novel therapy against serious fungal pathogens
Unlock access to complete
Unlock access to complete
Funding Insights of Scynexis
Scynexis has successfully raised a total of $62.65M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $10.0M
-
First Round
First Round
(20 Jun 2002)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2020 | Amount | Post-IPO - Scynexis | Valuation |
investors |
|
| Sep, 2016 | Amount | Debt – Conventional - Scynexis | Valuation |
investors |
|
| May, 2012 | Amount | Series D - Scynexis | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Scynexis
Scynexis has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Société Générale, SLR Investment Corp and Burrill and Company. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Debt and equity investments are offered by the firm.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on healthcare companies
|
Founded Year | Domain | Location | |
|
Limited information is provided about KBL Healthcare Ventures.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Scynexis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Scynexis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Scynexis Comparisons
Competitors of Scynexis
Scynexis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as F2g, Amplyx Pharmaceuticals, Biosergen, Elion Therapeutics and Viamet Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| domain | founded_year | HQ Location |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| domain | founded_year | HQ Location |
Anti-fungal therapeutics are developed against invasive fungal diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapies for chronic fungal infections are developed using metalloenzyme inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Scynexis
Frequently Asked Questions about Scynexis
When was Scynexis founded?
Scynexis was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Where is Scynexis located?
Scynexis is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.
Who is the current CEO of Scynexis?
Marco Taglietti is the current CEO of Scynexis.
Is Scynexis a funded company?
Scynexis is a funded company, having raised a total of $62.65M across 9 funding rounds to date. The company's 1st funding round was a Series D of $11.45M, raised on Jun 20, 2002.
How many employees does Scynexis have?
As of Dec 31, 2024, the latest employee count at Scynexis is 28.
What is the annual revenue of Scynexis?
Annual revenue of Scynexis is $3.75M as on Dec 31, 2024.
What does Scynexis do?
Developing glucan synthase inhibitors for the treatment of fungal infections. The companys lead candidate is SCY-078, which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections. SCY-078 acts as a glucan synthase inhibitor against a broad range of Candida and Aspergillus species.
Who are the top competitors of Scynexis?
Scynexis's top competitors include F2g, Amplyx Pharmaceuticals and Biosergen.
What products or services does Scynexis offer?
Scynexis offers SCY-247 and Ibrexafungerp.
Is Scynexis publicly traded?
Yes, Scynexis is publicly traded on NASDAQ under the ticker symbol SCYX.
Who are Scynexis's investors?
Scynexis has 11 investors. Key investors include Société Générale, SLR Investment Corp, Burrill and Company, Merial, and Puissance Capital.
What is Scynexis's ticker symbol?
The ticker symbol of Scynexis is SCYX on NASDAQ.